Return to the catalog
ARA-290
NewOut of stock10mg vial

ARA-290

Small peptide based on erythropoietin, studied for nerve repair and calming inflammation — without boosting red blood cells.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

Pricing coming soon

Contact us for a quote on this batch.

Bacteriostatic water included

99%+ Purity
Extensively Researched

About this peptide

ARA-290 (cibinetide) is an 11-amino-acid peptide designed specifically to protect and rebuild damaged nerves. It works by turning on the body's natural tissue repair switches, shutting down destructive local inflammation while shielding fragile nerve cells from further injury. In clinical trials for small-fibre nerve damage, ARA-290 was shown not just to calm burning neuropathic pain, but to actively stimulate the regrowth of healthy new nerve fibres—delivering powerful nerve protection and repair without affecting red blood cell counts.

Why researchers reach for ARA-290

Nerve-repair research

Human trials reported regrowth of small nerve fibres and reduced neuropathic pain.

Anti-inflammatory signalling

Studied for switching off inflammatory signalling and supporting tissue protection after injury.

No red-blood-cell effect

Activates EPO's protective receptor only, avoiding the blood-thickening effects of full EPO.

Key features

  • 99%+ purity verified by HPLC
  • Synthetic 11-amino-acid EPO-derived peptide
  • Lyophilised powder for stability
  • 10 mg research vial
  • Bacteriostatic water included
  • For laboratory research use only

How it works

Innate repair receptor

Selectively binds the EPO receptor / β-common receptor (CD131) complex, known as the innate repair receptor.

Cytokine dampening

Reduces release of pro-inflammatory cytokines such as TNF-α and IL-6 in injured tissue.

Neuroprotection

Promotes survival and regrowth of damaged small nerve fibres in animal and human studies.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Reported research range4 mgPer administration, as used subcutaneously in human trials (Brines et al., 2014–2015).
Frequency1× dailyClinical studies ran 28-day courses.
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL.

Tracking this compound? Registered researchers can log active ARA-290 protocols in their private Research Log.

Timing in research protocols

Once daily over 28-day courses — clock time not specified.

  • Human trials (Brines et al., 2014–2015) used 4 mg subcutaneously once daily for 28 days.
  • Time of day and meal relationship were not studied variables.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Scientific name
Cibinetide (pyroglutamate helix B surface peptide)
Sequence
pGlu-Glu-Trp-Leu-Glu-Arg-Ala-Arg-Asp-Gly-Ser-OH
CAS number
1208243-50-8
Molecular weight
~1257 Da
Purity
99%+ (HPLC)
Form
Lyophilised white powder
Vial size
10 mg
Reconstitution
2 ml bacteriostatic water
Storage (unopened)
-20 degrees C, protected from light
Storage (reconstituted)
2-8 degrees C, use within 30 days

Published research

Peer-reviewed literature on ARA-290. Links open in a new tab.

Research use notice

ARA-290 is supplied strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical application.

#ara-290#cibinetide#neuropathy#anti-inflammatory#tissue-repair

Cart (0)

Your cart is empty